CTRI/2015/05/005737已完成未知
A multicenter, randomized, open label, two treatment, two period,two sequence, single-dose, crossover, bioequivalence study ofMethotrexate Tablets 2.5 mg (manufactured for Actavis LLC) withMethotrexate Tablets USP 2.5 mg (DAVA Pharmaceuticals, Inc.,Fort Lee, NJ 07024 USA) in patients with mild to severe psoriasisor rheumatoid arthritis (RA), who are already on establishedregimens of 2.5 mg every 12 hours under fasting condition. - NA
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- Actavis LLC
- 入组人数
- 42
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Ba/be
入排标准
入选标准
- •1. Men or Women, in between 18 to 65 years of age (both inclusive).
- •2.Ability to provide informed consent prior to participation in the study
- •3. Patients with mild to severe psoriasis or rheumatoid arthritis, who are already on established regimens of 2.5 mgevery 12 hours (7.5 mg per week in three divided doses).
- •4.Confirmed diagnosis of psoriasis by clinical examination.or Confirmed diagnosis of mild to severe rheumatoid arthritis based on at least 1 of the following:
- •i. Documented history of positive rheumatoid factor
- •ii. Current presence of rheumatoid factor
- •iii. Radiographic erosion within 12 months prior to enrolment
- •iv. Presence of serum anti-cyclic citrullinated peptideantibodies (anti-CCP).
- •5. Women of childbearing potential must have a negative serum or urine pregnancy test, must be using an adequate method of contraception.
- •6.Patientâ??s screening laboratory assessment (complete blood count and blood chemistries) are clinically nonsignificant as per the discretion of the Investigator.
- •7. No history of addiction to any recreational drug or drug dependence.
- •8. No participation in any clinical study within the past 60 days.
排除标准
- •1.A history of allergic or adverse reactions to Methotraxate Sodium or any comparable or similar product
- •2. Patients with alcoholism, alcoholic liver disease or other chronic liver disease.
- •3.Patients who have overt or laboratory evidence of immunodeficiency syndromes.
- •4.Patients who have pre-existing blood dyscrasias, such as bone marrow hypoplasia, leukopenia, thrombocytopenia or significant anemia
- •5. Expected changes in concomitant medications during the period of study
- •6.Tested positive for Alcohol breath or Urine drug of abuse.
- •7.Patients who are:pregnant, breast feeding,Of childbearing potential without a negative pregnancy test at baseline, Male or female of childbearing potential unwilling to use barrier contraceptive precautions throughout the trial and at least for 3 months (for males) and for at least one ovulatory cycle (for females) after last dose of study medication, Patient had major surgery within 4 weeks prior to study entry, or who have not recovered from prior major surgery,Patients with known positivity for human
- •immunodeficiency virus (HIV), HBsAg and HCV, Patients with any significant history of non-compliance to medical regimens or with inability to grant a reliable informed consent.
- •8.History of difficulty with donating blood or difficulty in accessibility of veins.
- •9. Oral Administration of Drug is not possible.
- •10.An unusual or abnormal diet, for whatever reason e.g.religious fasting.
- •11.Donation of blood (1 unit or 350 ml) within 90 days prior to receiving the first dose of investigational medicinal product for the current study.
- •12.Evidence of any significant uncontrolled concomitant disease which in the investigators opinion would exclude the patient participation.
- •13. Patients with any evidence of organ dysfunction or any clinically significant deviation from normal in their physical or clinical evaluation including ECG and X-ray results except study indication.
- •14. Any treatment which could affect the pharmacokinetic of methotrexate (salicylates, hypoglycaemics, diuretics,sulphonamides, diphenylhydantoins, tetracyclines,chloramphenicol and p-aminobenzoic acid, probenecid,penicillins, Chloroquine, omeprazole, etretinate, cotrimoxazole and trimethoprim etc.) administered within 1 month of starting of study.
- •15.Patients who are diagnosed to be HIV 1 and 2 or Hepatitis B(HBsAg) or Hepatitis C (HCV) virus reactive/positive.
- •16. Patients with clinically significant abnormal haemoglobin(Hb), total white blood cells count (WBC), differential WBC count, platelet count and hematocrite.
- •17. Patients who, have clinically significant abnormal laboratory values.
- •18.Patients with a clinically significant past history or current medical condition of:Pulmonary disorders (COPD and asthma),Cardiovascular disorders (especially cardiac blocks), Neurological disorders, GIT disorders including history or presence of significant gastric and duodenal ulceration, Renal and/or hepatic disorder
- •coagulation disorders.
- •19.Endocrine disorders (especially diabetes mellitus).
- •20.History or presence of cancer.
研究者
相似试验
暂停
不适用
Bioequivalence study of Paliperidone Palmitate in schizophrenia patientsCTRI/2019/02/017754Amneal Pharmaceuticals Company GmbH
尚未招募
Unknown
This is a drug concentration assessment study of Azacitidine 300 mg tablets in patients with Blood Cancer (Acute Myeloid Leukemia).CTRI/2024/03/064636PLIVA Croatia Ltd
招募中
不适用
To compare bioavailibility of Methotrexate Tablets 2.5 mg( Amneal pharmaceuticals) with MethotrexateTablets USP 2.5 mg (DAVA Pharmaceuticals, Inc.USA) in patients with mild to severe psoriasisor rheumatoid arthritisCTRI/2016/06/007034Amneal Pharmaceuticals USA48
已完成
不适用
Two treatment Bioequivalence study of Methotrexate 2.5 mg in patients with Rheumatoid Arthritis (RA).CTRI/2022/09/045447Elite Pharmaceuticals48
招募中
不适用
This is a drug concentration assessment study of Azacitidine 300 mg tablets in patients with Blood Cancer (Acute Myeloid Leukemia).CTRI/2022/03/040956Watson Pharma Pvt Ltd